

Allergy Therapeutics PLC

1 ? . Ž ((f \$ & \$ + - , - ' \$, %
 B 5 . Ž % * (* , - * ' \$ *)
 51 Ž * % & - & , \$ \$ + \$ \$
 UWjcb4 dfcUWfj Y]bj Ygtrfg"Vta

07:54 25 Apr 2019

Allergy Therapeutics gets regulatory green light for phase III grass pollen trial

Allergy Therapeutics PLC (LON:AGY) has confirmed phase III trials of its short-course inoculation for grass pollen-induced hay fever will get underway in the second half of 2020.

This follows a successful round of meetings with both the German and American regulatory authorities that agreed the design and dosing of this pivotal study assessing the efficacy and safety of the aluminium-free immunotherapy.

Insights gained from recent clinical work will also be incorporated into the latest batch of tests, AT said. The trials will be overseen by the US Food & Drug Administration and the Paul Ehrlich Institut in Germany.

Chief executive Manuel Llobet told investors: "With the positive outcomes from our meetings with the FDA and Paul Ehrlich Institut, we have agreed design of our Phase III PQ Grass trial, including patient number requirements and statistical measures.

"Given the sensitivity of clinical trials in allergic rhinitis to the subjective nature of patient-reported outcomes, it is important that we incorporate any potential learnings from our recent trials into the final trial design for PQ Grass.

"Given the PQ Grass trial is expected to commence in the second-half of 2020 we are confident that we have time to amend the protocol accordingly if required.

"This product has the potential to become a much-needed treatment option for the estimated 25-30% of the EU and US populations who are allergic to grass pollen¹, and we believe that the PQ Grass trial will enable us to demonstrate the efficacy of this short-course grass pollen immunotherapy."

Well-funded and making progress

In wider update on the company's pipeline and financial position, AT said a read-out from a phase I clinical assessment of its Acarovac dust mite allergy drug was expected sometime in the current quarter.

Manufacturing scale-up of the Polyvac peanut product is progressing well ahead of a first-in-human study in the first half of next year, it added.

The commercial arm of the business, meanwhile, continued to trade in line with expectations, gaining market share. The company remains well-funded to "progress its commercial and clinical programme into 2021". As at the end of December AT had just under £32m in the bank.

"The potential of our pipeline is illustrated by the expected newsflow from our other clinical portfolio programmes and we look forward to updating the market as these progress," said CEO Llobet.

Price: 14.45

Market Cap: £92.09 m

1 Year Share Price Graph



Share Information

Code: AGY

Listing: AIM

52 week High Low
 15 7

Sector: Pharma & Biotech

Website: www.allergytherapeutics.com

Company Synopsis:

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).